Shares of Mesoblast Limited MESO have soared 80% in one month following the FDA approval of remestemcel-L as the only ...

Calquence is under clinical development by AstraZeneca and currently in Phase II for Graft Versus Host Disease (GVHD).

Progesterone is under clinical development by Glia and currently in Phase III for Graft Versus Host Disease (GVHD).

New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!

While gene therapy has emerged as a promising alternative for treating beta-thalassemia, hematopoietic stem cell ...

The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approv ...

Mesoblast's FDA approval for remestemcel marks a milestone for MSC therapies, but limited cash reserves pose risks for US ...

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

INR:6468. gta san 1 century-old miracle drug & 2 billion-dollar products & 4 blockbuster drugs: the future of antithrombotic drugs is still promising Strategies for the d ...

Sergio A. Giralt, MD, discusses how the pathophysiology of chronic graft-vs-host disease involves complex immune dysregulation, with CSF1R playing a crucial role in driving the differentiation of ...

The basis of the issued patent stems from the pioneering basic and clinical research work in the use of topical DNase conducted by Sandeep Jain, M.D., BA Field Professor of Ophthalmology and Director ...

INR:8172. mobile app Roche releases new data from two-year study of risdiplam in infants, children and adults with SMA Shengde's diabetes drug candidate CS02 Phase II ...